Published in Am J Public Health on August 19, 2010
Acute HIV-1 Infection. N Engl J Med (2011) 4.84
HIV prevention transformed: the new prevention research agenda. Lancet (2011) 4.23
Antiviral agents and HIV prevention: controversies, conflicts, and consensus. AIDS (2012) 1.73
Human leukocyte antigen (HLA) class I down-regulation by human immunodeficiency virus type 1 negative factor (HIV-1 Nef): what might we learn from natural sequence variants? Viruses (2012) 1.48
Interactions of HIV, other sexually transmitted diseases, and genital tract inflammation facilitating local pathogen transmission and acquisition. Am J Reprod Immunol (2011) 1.32
Project enhance: a randomized controlled trial of an individualized HIV prevention intervention for HIV-infected men who have sex with men conducted in a primary care setting. Health Psychol (2012) 1.19
Epistemic fault lines in biomedical and social approaches to HIV prevention. J Int AIDS Soc (2011) 1.14
Intravaginal rings as delivery systems for microbicides and multipurpose prevention technologies. Int J Womens Health (2013) 1.05
Clinician practices and attitudes regarding early antiretroviral therapy in the United States. J Acquir Immune Defic Syndr (2012) 0.99
Durable knockdown and protection from HIV transmission in humanized mice treated with gel-formulated CD4 aptamer-siRNA chimeras. Mol Ther (2013) 0.95
Sexual risk behaviors among HIV-infected South African men and women with their partners in a primary care program: implications for couples-based prevention. AIDS Behav (2012) 0.95
Sexual healthcare preferences among gay and bisexual men: a qualitative study in San Francisco, California. PLoS One (2013) 0.95
HIV treatment for prevention. J Int AIDS Soc (2011) 0.93
Patterns of condom use and associated factors among adult HIV positive clients in North Western Ethiopia: a comparative cross sectional study. BMC Public Health (2012) 0.90
Immune-mediated attenuation of HIV-1. Future Virol (2011) 0.89
Experience in international clinical research: the HIV Prevention Trials Network. Clin Investig (Lond) (2011) 0.84
Preserving human rights in the era of "test and treat" for HIV prevention. Am J Public Health (2011) 0.80
Predictive models for maximum recommended therapeutic dose of antiretroviral drugs. Comput Math Methods Med (2012) 0.79
Comparison of auditory brainstem response in HIV-1 exposed and unexposed newborns and correlation with the maternal viral load and CD4+ cell counts. AIDS (2014) 0.76
Consistent condom use in HIV/AIDS patients receiving antiretroviral therapy in northwestern Ethiopia: implication to reduce transmission and multiple infections. HIV AIDS (Auckl) (2015) 0.76
High burden of STIs among HIV-infected adults prior to initiation of ART in South Africa: a retrospective cohort study. Sex Transm Infect (2014) 0.75
Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med (1998) 53.26
Viral load and heterosexual transmission of human immunodeficiency virus type 1. Rakai Project Study Group. N Engl J Med (2000) 41.18
Universal voluntary HIV testing with immediate antiretroviral therapy as a strategy for elimination of HIV transmission: a mathematical model. Lancet (2008) 36.01
Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. Pediatric AIDS Clinical Trials Group Protocol 076 Study Group. N Engl J Med (1994) 25.02
Rates of HIV-1 transmission per coital act, by stage of HIV-1 infection, in Rakai, Uganda. J Infect Dis (2005) 21.08
From epidemiological synergy to public health policy and practice: the contribution of other sexually transmitted diseases to sexual transmission of HIV infection. Sex Transm Infect (1999) 17.95
Heterosexual HIV-1 transmission after initiation of antiretroviral therapy: a prospective cohort analysis. Lancet (2010) 16.90
Control of sexually transmitted diseases for AIDS prevention in Uganda: a randomised community trial. Rakai Project Study Group. Lancet (1999) 10.28
Prevention of mother-to-child HIV transmission in resource-poor countries: translating research into policy and practice. JAMA (2000) 10.17
Antiretroviral-drug resistance among patients recently infected with HIV. N Engl J Med (2002) 9.70
Prevention of SIV infection in macaques by (R)-9-(2-phosphonylmethoxypropyl)adenine. Science (1995) 9.48
Changes in sexual behavior and risk of HIV transmission after antiretroviral therapy and prevention interventions in rural Uganda. AIDS (2006) 9.45
Effect of aciclovir on HIV-1 acquisition in herpes simplex virus 2 seropositive women and men who have sex with men: a randomised, double-blind, placebo-controlled trial. Lancet (2008) 9.17
Brief but efficient: acute HIV infection and the sexual transmission of HIV. J Infect Dis (2004) 8.30
Decline in the AIDS and death rates in the EuroSIDA study: an observational study. Lancet (2003) 7.94
High rates of forward transmission events after acute/early HIV-1 infection. J Infect Dis (2007) 7.70
Detection of acute infections during HIV testing in North Carolina. N Engl J Med (2005) 7.60
Effect of herpes simplex suppression on incidence of HIV among women in Tanzania. N Engl J Med (2008) 7.49
Behavioural strategies to reduce HIV transmission: how to make them work better. Lancet (2008) 7.42
The case for expanding access to highly active antiretroviral therapy to curb the growth of the HIV epidemic. Lancet (2006) 7.17
Narrative review: antiretroviral therapy to prevent the sexual transmission of HIV-1. Ann Intern Med (2007) 7.14
A case-control study of HIV seroconversion in health care workers after percutaneous exposure. Centers for Disease Control and Prevention Needlestick Surveillance Group. N Engl J Med (1997) 7.11
Highly active antiretroviral therapy and sexual risk behavior: a meta-analytic review. JAMA (2004) 7.04
Heterosexual risk of HIV-1 infection per sexual act: systematic review and meta-analysis of observational studies. Lancet Infect Dis (2009) 6.96
Sexual transmission of HIV. N Engl J Med (1997) 6.84
Integrating HIV prevention and treatment: from slogans to impact. PLoS Med (2005) 6.73
HIV-1 transmission, by stage of infection. J Infect Dis (2008) 6.57
Risk of human immunodeficiency virus infection in herpes simplex virus type 2-seropositive persons: a meta-analysis. J Infect Dis (2001) 6.35
Reduction of concentration of HIV-1 in semen after treatment of urethritis: implications for prevention of sexual transmission of HIV-1. AIDSCAP Malawi Research Group. Lancet (1997) 6.34
Impact of highly active antiretroviral treatment on HIV seroincidence among men who have sex with men: San Francisco. Am J Public Health (2002) 6.01
Virologic and immunologic determinants of heterosexual transmission of human immunodeficiency virus type 1 in Africa. AIDS Res Hum Retroviruses (2001) 6.00
Rethinking the heterosexual infectivity of HIV-1: a systematic review and meta-analysis. Lancet Infect Dis (2008) 5.85
Preexposure antiretroviral prophylaxis attitudes in high-risk Boston area men who report having sex with men: limited knowledge and experience but potential for increased utilization after education. J Acquir Immune Defic Syndr (2009) 5.48
Updated U.S. Public Health Service Guidelines for the Management of Occupational Exposures to HBV, HCV, and HIV and Recommendations for Postexposure Prophylaxis. MMWR Recomm Rep (2001) 5.34
Chemoprophylaxis with tenofovir disoproxil fumarate provided partial protection against infection with simian human immunodeficiency virus in macaques given multiple virus challenges. J Infect Dis (2006) 5.24
Limited knowledge and use of HIV post- and pre-exposure prophylaxis among gay and bisexual men. J Acquir Immune Defic Syndr (2008) 5.05
Antiretroviral postexposure prophylaxis after sexual, injection-drug use, or other nonoccupational exposure to HIV in the United States: recommendations from the U.S. Department of Health and Human Services. MMWR Recomm Rep (2005) 5.03
Effectiveness of highly active antiretroviral therapy in reducing heterosexual transmission of HIV. J Acquir Immune Defic Syndr (2005) 4.96
Tenofovir disoproxil fumarate for prevention of HIV infection in women: a phase 2, double-blind, randomized, placebo-controlled trial. PLoS Clin Trials (2007) 4.93
Potent antiretroviral treatment of HIV-infection results in suppression of the seminal shedding of HIV. The Swiss HIV Cohort Study. AIDS (2000) 4.91
Simian immunodeficiency virus rapidly penetrates the cervicovaginal mucosa after intravaginal inoculation and infects intraepithelial dendritic cells. J Virol (2000) 4.87
Viral burden in genital secretions determines male-to-female sexual transmission of HIV-1: a probabilistic empiric model. AIDS (2001) 4.76
Complete protection from repeated vaginal simian-human immunodeficiency virus exposures in macaques by a topical gel containing tenofovir alone or with emtricitabine. J Virol (2009) 4.73
AIDS. Promote HIV chemoprophylaxis research, don't prevent it. Science (2005) 4.44
Seroconversion following nonoccupational postexposure prophylaxis against HIV. Clin Infect Dis (2005) 4.27
Safety and tolerability of tenofovir vaginal gel in abstinent and sexually active HIV-infected and uninfected women. AIDS (2006) 4.23
Decreased HIV transmission after a policy of providing free access to highly active antiretroviral therapy in Taiwan. J Infect Dis (2004) 4.17
Time trends in primary HIV-1 drug resistance among recently infected persons. JAMA (2002) 4.02
The World Health Organization's global strategy for prevention and assessment of HIV drug resistance. Antivir Ther (2008) 4.00
Behavioral impact, acceptability, and HIV incidence among homosexual men with access to postexposure chemoprophylaxis for HIV. J Acquir Immune Defic Syndr (2004) 3.86
An HIV vaccine--evolving concepts. N Engl J Med (2007) 3.78
The role of early HIV infection in the spread of HIV through populations. J Acquir Immune Defic Syndr Hum Retrovirol (1997) 3.75
Amplified transmission of HIV-1: comparison of HIV-1 concentrations in semen and blood during acute and chronic infection. AIDS (2007) 3.72
Sexual risk, nitrite inhalant use, and lack of circumcision associated with HIV seroconversion in men who have sex with men in the United States. J Acquir Immune Defic Syndr (2005) 3.54
Circumcision status and risk of HIV and sexually transmitted infections among men who have sex with men: a meta-analysis. JAMA (2008) 3.51
Effect of antiviral treatment on the shedding of HIV-1 in semen. AIDS (1997) 3.42
Changes in sexual risk behavior among participants in a PrEP HIV prevention trial. Sex Transm Dis (2008) 3.31
Emergence of drug resistance in HIV type 1-infected patients after receipt of first-line highly active antiretroviral therapy: a systematic review of clinical trials. Clin Infect Dis (2008) 3.15
Human immunodeficiency virus type 1 in the semen of men receiving highly active antiretroviral therapy. N Engl J Med (1998) 3.14
Tenofovir DF plus lamivudine or emtricitabine for nonoccupational postexposure prophylaxis (NPEP) in a Boston Community Health Center. J Acquir Immune Defic Syndr (2008) 3.10
Recent observations on HIV type-1 infection in the genital tract of men and women. AIDS (2003) 2.97
Potential impact of antiretroviral chemoprophylaxis on HIV-1 transmission in resource-limited settings. PLoS One (2007) 2.84
Phase i/ii trial of the pharmacokinetics, safety, and antiretroviral activity of tenofovir disoproxil fumarate in human immunodeficiency virus-infected adults. Antimicrob Agents Chemother (2001) 2.84
Antiretroviral drug-based microbicides to prevent HIV-1 sexual transmission. Annu Rev Med (2008) 2.81
The effect of treatment of vaginal infections on shedding of human immunodeficiency virus type 1. J Infect Dis (2001) 2.79
HIV-1 subtype C viruses rapidly develop K65R resistance to tenofovir in cell culture. AIDS (2006) 2.77
Effect of highly active antiretroviral therapy on cervicovaginal HIV-1 RNA. AIDS (2000) 2.61
Attitudes towards highly active antiretroviral therapy are associated with sexual risk taking among HIV-infected and uninfected homosexual men. AIDS (2002) 2.57
Association between bacterial vaginosis and expression of human immunodeficiency virus type 1 RNA in the female genital tract. Clin Infect Dis (2001) 2.49
Antiretroviral therapy and sexual behavior: a comparative study between antiretroviral- naive and -experienced patients at an urban HIV/AIDS care and research center in Kampala, Uganda. AIDS Patient Care STDS (2005) 2.48
Modelling the effect of combination antiretroviral treatments on HIV incidence. AIDS (2001) 2.48
Male viral load and heterosexual transmission of HIV-1 subtype E in northern Thailand. J Acquir Immune Defic Syndr (2002) 2.48
Frequent detection of acute primary HIV infection in men in Malawi. AIDS (2004) 2.43
Sexual risk behaviour relates to the virological and immunological improvements during highly active antiretroviral therapy in HIV-1 infection. AIDS (2001) 2.41
Sexual risk behaviors and implications for secondary HIV transmission during and after HIV seroconversion. AIDS (2002) 2.33
Effects of disease stage and zidovudine therapy on the detection of human immunodeficiency virus type 1 in semen. JAMA (1992) 2.32
The impact of HIV treatment on risk behaviour in developing countries: a systematic review. AIDS Care (2007) 2.17
No HIV stage is dominant in driving the HIV epidemic in sub-Saharan Africa. AIDS (2008) 2.04
Access to antiretroviral treatment and sexual behaviours of HIV-infected patients aware of their serostatus in Côte d'Ivoire. AIDS (2003) 2.04
Where does HIV live? N Engl J Med (2004) 1.96
Amplified HIV transmission and new approaches to HIV prevention. J Infect Dis (2005) 1.95
Knowledge and use of HIV pre-exposure prophylaxis among attendees of minority gay pride events, 2004. J Acquir Immune Defic Syndr (2006) 1.93
Increase in sexual risk behavior associated with immunologic response to highly active antiretroviral therapy among HIV-infected injection drug users. Clin Infect Dis (2004) 1.89
Treatment of cervicitis is associated with decreased cervical shedding of HIV-1. AIDS (2001) 1.88
T lymphocytes and macrophages, but not motile spermatozoa, are a significant source of human immunodeficiency virus in semen. J Infect Dis (1997) 1.85
Two drugs or three? Balancing efficacy, toxicity, and resistance in postexposure prophylaxis for occupational exposure to HIV. Clin Infect Dis (2004) 1.78
Resistance of HIV-1 to antiretroviral agents in blood and seminal plasma: implications for transmission. AIDS (1998) 1.59
The pharmacokinetics and viral activity of tenofovir in the male genital tract. J Acquir Immune Defic Syndr (2008) 1.55
Pathology and localization of simian immunodeficiency virus in the reproductive tract of chronically infected male rhesus macaques. Lab Invest (1994) 1.50
Protease inhibitor and nonnucleoside reverse transcriptase inhibitor concentrations in the genital tract of HIV-1-infected women. J Acquir Immune Defic Syndr (2004) 1.45
Penetration of enfuvirtide, tenofovir, efavirenz, and protease inhibitors in the genital tract of HIV-1-infected men. AIDS (2004) 1.44
Association of CD4 cell depletion and elevated blood and seminal plasma human immunodeficiency virus type 1 (HIV-1) RNA concentrations with genital ulcer disease in HIV-1-infected men in Malawi. J Infect Dis (1998) 1.42
Disinhibition and risk compensation: scope, definitions, and perspective. Sex Transm Dis (2008) 1.41
Localization of Simian immunodeficiency virus-infected cells in the genital tract of male and female Rhesus macaques. J Reprod Immunol (1998) 1.41
Can antiretroviral therapy be used to prevent sexual transmission of human immunodeficiency virus type 1? Clin Infect Dis (2002) 1.33
Nucleoside analogues achieve high concentrations in seminal plasma: relationship between drug concentration and virus burden. J Infect Dis (1999) 1.32
Sequential emergence and clinical implications of viral mutants with K70E and K65R mutation in reverse transcriptase during prolonged tenofovir monotherapy in rhesus macaques with chronic RT-SHIV infection. Retrovirology (2007) 1.28
Antiretroviral drug concentrations in semen of HIV-1 infected men. Sex Transm Infect (2001) 1.27
Genital tract HIV-1 RNA shedding among women with below detectable plasma viral load. AIDS (2010) 2.33
High frequency of clinically significant mutations after first-line generic highly active antiretroviral therapy failure: implications for second-line options in resource-limited settings. Clin Infect Dis (2009) 2.17
Safety, tolerability and effectiveness of generic HAART in HIV-infected children in South India. J Trop Pediatr (2008) 1.63
Interactions of HIV, other sexually transmitted diseases, and genital tract inflammation facilitating local pathogen transmission and acquisition. Am J Reprod Immunol (2011) 1.32
Spectrum of adverse events after generic HAART in southern Indian HIV-infected patients. AIDS Patient Care STDS (2008) 1.26
Factors associated with mortality among HIV-infected patients in the era of highly active antiretroviral therapy in southern India. Int J Infect Dis (2009) 1.04
Effect of treatment of asymptomatic bacterial vaginosis on HIV-1 shedding in the genital tract among women on antiretroviral therapy: a pilot study. Clin Infect Dis (2009) 0.92
A longitudinal quality-of-life study of HIV-infected persons in South India: the case for comprehensive clinical care and support services. AIDS Educ Prev (2009) 0.90
Safety, Tolerability, and Efficacy of Second-Line Generic Protease Inhibitor Containing HAART after First-Line Failure among South Indian HIV-Infected Patients. J Int Assoc Physicians AIDS Care (Chic) (2011) 0.85
Safe substitution to zidovudine among HIV-infected patients initiated on stavudine-containing highly active antiretroviral therapy from a resource-limited setting. Int J Infect Dis (2009) 0.83
Chemoprophylaxis for HIV prevention: new opportunities and new questions. J Acquir Immune Defic Syndr (2010) 0.82
Challenges of expansion of voluntary counselling and testing in India. Sex Health (2008) 0.82
Changes in antioxidant profile among HIV-infected individuals on generic highly active antiretroviral therapy in southern India. Int J Infect Dis (2008) 0.81
Opportunities and options for the use of protease inhibitors in a resource-poor setting: experiences from southern India. J Acquir Immune Defic Syndr (2007) 0.80
Clinical outcomes among HIV/tuberculosis-coinfected patients developing immune reconstitution inflammatory syndrome after HAART initiation in South India. J Int Assoc Provid AIDS Care (2012) 0.78
Expansion of HIV laboratory diagnostic services in Chennai, India 2001-2006: is the growth commensurate with the need? PLoS One (2008) 0.77
The social ecology of HIV/AIDS. Med Clin North Am (2008) 0.77
Safety of switching to nevirapine-based highly active antiretroviral therapy at elevated CD4 cell counts in a resource-constrained setting. J Acquir Immune Defic Syndr (2007) 0.75
Health care policy under President Romney. N Engl J Med (2012) 0.75
Clinical Risk Factors Associated With Peripartum Maternal Bacteremia. Obstet Gynecol (2017) 0.75